A study found a "high rate of substitution" between vapes and cigarettes, suggesting that policies aimed at preventing underage use are undermining public health.
Removing high tariffs from foreign imports of baby formula would ease the supply shock of possible factory closures.
The founder of MAPS talks about FDA approval for MDMA-assisted therapy and the "psychedelic renaissance" he has helped create.
The 1988 case highlighted the DEA's stubborn insistence that marijuana has no "accepted medical use."
Although the HHS-recommended change would benefit researchers and the cannabis industry, it would not resolve the conflict between state and federal marijuana laws.
The U.S. Court of Appeals for the D.C. Circuit takes issue with how the FDA evaluated Fontem's unflavored vaping products.
While schoolchildren go without needed medication, government agencies shirk responsibility by blaming manufacturers.
Painkiller reflects an indiscriminate anti-opioid bias that has caused needless suffering.
Plus: Court urged to stop Arkansas' social media age verification law from taking effect in September, legalizing medical marijuana linked to lower insurance premiums, and more...
On this one issue, the democratic socialist sounds a lot like a libertarian.
A combination of "absurdly high" federal tariffs and excessive FDA regulations created the conditions for a crisis.
No one could have considered this possibility, except perhaps the many food-processing facilities that immediately did exactly that.
A recent House committee investigation exposed political interference when it came to figuring out the origins of COVID. But why?
The FDA decision is only a mini step toward freeing the pill.
The new energy drink has about as much caffeine as a large Starbucks coffee.
As beef prices increase, biotech could provide a cheaper and tasty alternative.
His licensing proposal would slow down A.I. innovation without really reducing A.I. risks.
A recent study finds that human challenge trials are largely safe.
Plus: No one is excited about a 2024 rematch between Biden and Trump, it's showtime for House Republicans' debt ceiling bill, and more...
Mifepristone will remain on the market for now with no changes to how it can be prescribed.
Officials who often get it wrong can’t be trusted to reliably decree what’s true.
The appeals court's unpublished order avoids some of the district court's errors, but still has some significant problems, especially with regard to standing.
It’s not the FDA’s job to tell doctors what to do.
Plus: The editors respond to a listener question concerning corporate personhood.
The divergent orders from judges in Washington state and Texas may bring the battle over mifepristone to the Supreme Court.
Litigation over abortion drugs turns disagreements about individual rights into a bureaucratic tussle.
And this lawsuit faces many of the same administrative law hurdles as does AHM v. FDA.
The life-saving drug stops opioid overdoses as they happen, restoring breathing and preventing death. Why did it take so long for the FDA to expand its use?
Thanks to onerous regulations, life-saving drugs are more expensive and harder to get.
Huh, what a wild coincidence.
The 5th Circuit Rebukes the FDA for Flouting the Law While Imposing a De Facto Ban on Flavored E-Cigarettes
The appeals court says regulators violated the Administrative Procedure Act when they tried to pull menthol vapes off the market.
Another opinion exposing the Food and Drug Administration's vaping problem.
There's been lots of heat, but very little light in coverage and commentary about the lawsuit seeking to revoke FDA approval of mifepristone.
The outspoken critic of the CDC and FDA explains what went wrong—and what went right—with COVID policy.
The agency's action ignores the government's own role in creating a black market in the first place.